Show
Sort by
-
Managing psoriasis anno 2018 : a route towards personalising treatment
(2018) -
- Journal Article
- A2
- open access
Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor : case report and literature review
-
- Journal Article
- A1
- open access
Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation
-
- Journal Article
- A1
- open access
Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases
-
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
-
In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research
-
Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines
-
Role of the HLA-C*06 allele in clinical response to ustekinumab : evidence from real life in a large cohort of European patients
-
Secukinumab : IL-17A inhibition to treat psoriatic arthritis
-
A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis : results of the PALACE 2 trial